Overview

Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC

Status:
Unknown status
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of weekly administered combination of docetaxel/cisplatin and docetaxel/oxaliplatin in chemotherapy-naïve patients with advanced gastric cancer. The primary endpoint will be the response rate.
Phase:
Phase 2
Details
Lead Sponsor:
Gachon University Gil Medical Center
Collaborator:
Sanofi
Treatments:
Cisplatin
Docetaxel
Oxaliplatin